Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.45 |
| ▸ | ITGAV | P06756 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575082 | 0.91 | GAA (0.46) | GAASMN1; SMN2LMNAITGB1ITGA4 | |
| SCHEMBL1574911 | 0.89 | GRIN2B (0.58) | SMN1; SMN2LMNAKMT2AGRIN2B | |
| SCHEMBL1575210 | 0.89 | RAB9A (0.50) | KMT2AGRIN2B | |
| SCHEMBL1574665 | 0.88 | TAAR1 (0.50) | GAALMNAKMT2AGRIN2BKDM4E | |
| SCHEMBL1575019 | 0.88 | POLB (0.49) | GAALMNAGRIN2BKDM4E | |
| SCHEMBL1575172 | 0.87 | KDM4E (0.58) | GAASMN1; SMN2KMT2AGRIN2BEPHX2 | |
| SCHEMBL1574890 | 0.87 | GAA (0.51) | GAASMN1; SMN2LMNAKMT2AP2RX7 | |
| SCHEMBL1574559 | 0.85 | KDM4E (0.56) | LMNAKMT2AKDM4E | |
| SCHEMBL1574669 | 0.85 | GAA (0.51) | GAASMN1; SMN2LMNAITGB1ITGA4 | |
| SCHEMBL1575133 | 0.85 | HPGD (0.52) | SMN1; SMN2KMT2AGRIN2BKDM4EFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-B1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | GAA 387/4885SMN1; SMN2 1838/4885LMNA 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.